Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011210 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL2251073 | 0.98 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL7653360 | 0.92 | ALDH1A1 (0.50) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL4074831 | 0.89 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL28686443 | 0.87 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL28265469 | 0.87 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL2532080 | 0.87 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL28299062 | 0.87 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL2532077 | 0.87 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL17023983 | 0.85 | NAAA (0.47) | NAAAEPHX1TSHRHCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024179934-A1 | COMPOSITION | SYNGENTA CROP PROTECTION AG (CH) | 2024-09-06 | — | — | WO | claimed |
| WO-2023126852-A1 | BATCH DISTILLATION METHOD AND BATCH DISTILLATION COLUMN WITH SIDE DISCHARGE POINT | DE NEEF CHEMICAL PROCESSING N.V. (BE) | 2023-07-06 | — | — | WO | claimed |
| US-11576375-B2 | Dispersible herbicidal compositions and methods of use | AMVAC CHEMICAL CORPORATION (US) | 2023-02-14 | — | — | US | claimed |
| WO-2022229984-A1 | NATURAL COMPOSITION OF PLANT EXTRACTS TO CONTROL PARASITIC PATHOGENS AND PLANT NEMATODES | AHIRE MRS SUNITA (IN) | 2022-11-03 | — | — | WO | claimed |
| EP-3692981-B1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | CHEM CURE ASS LLC (US) | 2022-05-04 | — | — | EP | claimed |
| US-11260063-B2 | Method and compositions for treating psoriasis | CHEM-CURE ASSOCIATES LLC (US) | 2022-03-01 | — | — | US | claimed |
| EP-3692981-A1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | Anaplasi Pharmaceuticals LLC (US) | 2020-08-12 | — | — | EP | claimed |
| US-20200129529-A1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI Pharmaceuticals, LLC (US) | 2020-04-30 | — | — | US | claimed |
| EP-3305299-B1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI PHARMACEUTICALS LLC (US) | 2020-04-29 | — | — | EP | claimed |
| US-20200102255-A1 | NEW METHOD FOR FERTILIZING AGRICULTURAL SOIL | BASF CORPORATION | 2020-04-02 | — | — | US | claimed |
| US-20050169951-A1 | Pesticidal composition comprising a lactate ester as crystal growth inhibitor | MAKHTESHIM CHEMICAL WORKS LTD (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005048952-A2 | COMPOSITION AND DOSAGE FORM COMPRISING AN AMPHIPHILIC MOLECULE AS A SUSPENSION VEHICLE | ALZA CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| WO-2005049719-A2 | AQUEOUS COMPOSITIONS COMPRISING ESTERS OF LACTIC ACID AND METHODS OF USE | OMNOVA SOLUTIONS INC. (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050112188-A1 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | INTARCIA THERAPEUTICS, INC. | 2005-05-26 | — | — | US | claimed |
| EP-1482790-A1 | PESTICIDAL COMPOSITION COMPRISING A LACTATE ESTER AS CRYSTAL GROWTH INHIBITOR | Makhteshim Chemical Works Ltd., IP Dept. (IL) | 2004-12-08 | — | — | EP | claimed |
| WO-2003075657-A1 | PESTICIDAL COMPOSITION COMPRISING A LACTATE ESTER AS CRYSTAL GROWTH INHIBITOR | MAKHTESHIM CHEMICAL WORKS LTD. (IL) | 2003-09-18 | — | — | WO | claimed |
| WO-2002060852-A2 | PROCESS FOR THE PREPARATION OF ALKYL LACTATES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-08-08 | — | — | WO | claimed |
| US-6342626-B1 | ESTERIFICATION AND HYDROLYSIS OF LACTIC ACID | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-01-29 | — | — | US | claimed |
| WO-2001092025-A1 | PAINT COMPOSITION, PAINT SET AND DIGITAL PRINTING PROCESS | BECKER INDUSTRIAL COATINGS LIMITED (GB) | 2001-12-06 | — | — | WO | claimed |
| US-6294508-B1 | CUTTING OILS AND ABRASIVES | 3M INNOVATIVE PROPERTIES COMPANY | 2001-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576375-B2 | Dispersible herbicidal compositions and methods of use | DDT, HDHD5, GMDS | NAAA 41/4885EPHX1 54/4885TSHR 4194/4885 |
| US-20050112188-A1 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | ANXA6, SLC47A2, SLC47A1 | NAAA 3219/4885EPHX1 3531/4885TSHR 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.